Natco gets USFDA nod for Nitroglycerin sublingual tablets

Natco Pharma’s marketing partner Alvogen has received final approval of Abbreviated New Drug Application (ANDA) from USFDA for Nitroglycerin Sublingual Tablets USP, 0.3 mg, 0.4 mg, and 0.6 mg.

Nitroglycerin sublingual tablets are used to treat episodes of angina (chest pain) in people who have coronary artery disease (narrowing of the blood vessels that supply blood to the heart).

Pfizer Pharmaceuticals markets this drug under its brand Nitrostat Sublingual Tablets in the same strengths. As per IQVIA data, Nitroglycerin Sublingual Tablets had total annual sales of around US$ 77.3 million in the US market, for the year ending 2018.

Also, last week, the company got approval from USFDA for Bosentan tablets in the strengths of 62.5 mg and 125 mg which is used for the treatment of patients with pulmonary arterial hypertension.

On Wednesday, the stock of Natco Pharma opened at Rs. 532 per share on BSE. In the morning session, it touched Rs. 534.45 and later got corrected to Rs. 528 level.